10-Q: Avinger Inc. Reports Q2 2024 Results Amidst Strategic Realignment and Financial Restructuring

Avinger Inc. announced its Q2 2024 financial results, highlighting a strategic realignment and cost reduction plan, alongside ongoing efforts to secure financial stability.

Summary

• Avinger Inc. reported a net loss of $4.4 million for the three months ended June 30, 2024, and a net loss of $9.9 million for the six months ended June 30, 2024.
• Revenue for the quarter was $1.8 million, a 10% decrease compared to the same period last year, while revenue for the six months was $3.7 million, a 6% decrease compared to the same period last year.
• The company's gross margin decreased to 20% for the quarter and 19% for the six months, down from 30% and 32% respectively in the prior year periods.
• Avinger undertook a strategic realignment and cost reduction plan in June 2024, which included a 24% reduction in workforce.
• The company completed a public offering in June 2024, raising approximately $5.2 million in net proceeds.
• Avinger also entered into a strategic collaboration with Zylox-Tonbridge, receiving $7.5 million in initial funding and the potential for an additional $7.5 million upon achieving certain milestones.
• The company's cash and cash equivalents stood at $8.8 million as of June 30, 2024.
• Avinger believes its current cash and cash equivalents, along with expected revenues and financing activities, will be sufficient to fund operations through the end of the fourth quarter of 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has secured some funding and made strategic moves, the financial results are weak, and there are significant concerns about its ability to continue as a going concern. The strategic realignment and workforce reduction also indicate challenges.

Positives

• Avinger successfully raised $5.2 million through a public offering in June 2024.
• The strategic collaboration with Zylox-Tonbridge provides access to new markets and potential for additional funding.
• The conversion of $11.0 million of debt into equity improved the company's balance sheet.
• The company has extended its interest-only period on its loan with CRG through December 31, 2026.
• Avinger has regained compliance with Nasdaq's stockholders equity requirement.

Negatives

• Avinger experienced a 10% decrease in revenue in Q2 2024 compared to the same period last year.
• The company's gross margin decreased to 20% in Q2 2024.
• Avinger incurred a net loss of $4.4 million for the three months ended June 30, 2024.
• The company reduced its workforce by 24% in June 2024.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• Avinger's ability to continue as a going concern is uncertain, requiring additional financing.
• The company's debt obligations are classified as current due to going concern doubts and a Material Adverse Change clause in the loan agreement.
• The company may not be able to maintain compliance with Nasdaq listing requirements.
• The company's future success depends on its ability to commercialize products and raise additional funding.
• The company faces risks related to global supply chain disruptions and inflationary pressures.
• The company's revenue is concentrated with a few customers, posing a risk if those relationships are disrupted.

Future Outlook

Avinger expects its current cash and cash equivalents, along with expected revenues and financing activities, will be sufficient to fund operations through the end of the fourth quarter of 2024. The company anticipates needing additional capital through future equity or debt financings to meet operational needs and capital requirements for product development, clinical trials, and commercialization.

Management Comments

• Management believes that its cash and cash equivalents of $8.8 million at June 30, 2024, together with debt and other financing activities and expected revenues from operations will be sufficient to allow the Company to fund its current operations through the end of the fourth quarter of 2024.
• Management believes that the data from VISION allows us to demonstrate that avoiding damage to healthy arterial structures, and in particular disruption of the external elastic lamina, which is the membrane between the outermost layers of the artery, reduces the likelihood of restenosis, or re-narrowing, of the diseased artery.

Industry Context

Avinger operates in the competitive medical device industry, specifically in the peripheral artery disease (PAD) market. The company's Lumivascular platform, which integrates optical coherence tomography (OCT) visualization with interventional catheters, is a unique offering in this space. The company is also developing next-generation CTO crossing devices to target the coronary CTO market, which is a highly competitive area.

Comparison to Industry Standards

• Avinger's gross margin of 20% for the quarter and 19% for the six months is lower than the typical gross margins seen in the medical device industry, which often range from 50% to 70%.
• Companies like Medtronic and Abbott, which are major players in the medical device industry, typically have much higher revenue and profitability due to their scale and diversified product portfolios.
• Avinger's focus on image-guided atherectomy and CTO crossing devices is a niche market compared to the broader cardiovascular device market, which includes stents, pacemakers, and other devices.
• The company's reliance on a single manufacturing facility and a limited number of suppliers also poses a risk compared to larger companies with more diversified supply chains.
• Avinger's cash position of $8.8 million is relatively low compared to larger medical device companies, which often have hundreds of millions or billions in cash reserves.

Management Changes

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment if the company fails.
• Employees have been impacted by the workforce reduction in June 2024.
• Customers may experience some disruption due to the company's strategic realignment.
• Suppliers may be affected by the company's financial challenges and potential restructuring.
• Creditors face the risk of non-payment if the company is unable to meet its debt obligations.

Next Steps

• Avinger will focus on driving catheter utilization in its strongest peripheral markets.
• The company will continue to develop its coronary device program.
• Avinger will work towards achieving the milestones required to receive the additional $7.5 million from Zylox-Tonbridge.
• The company will seek additional financing to meet its operational needs and capital requirements.

Key Dates

Keywords

Avinger, Lumivascular, Pantheris, Ocelot, Tigereye, atherectomy, peripheral artery disease, PAD, medical devices, financial results, strategic collaboration, capital raise, Nasdaq, going concern